The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer
Open accessAbstract
BACKGROUND: HER-2/neu, which encodes a receptor tyrosine kinase, is amplified and overexpressed in 20%-25% of human breast cancers. Such tumors are often resistant to hormone therapy. Despite a general inverse association between HER-2/neu amplification/overexpression and estrogen receptor (ER) and/or progesterone receptor (PR) expression, a fraction of patients are both HER-2/neu- and hormone receptor (HR)-positive. The efficacy of hormone therapy in this group is currently a matter of debate. To better understand the relationship between HER-2/neu positivity and HR expression, we analyzed HER-2/neu, ER, and PR as continuous variables in breast cancer cell lines and two cohorts of primary breast cancer patients. METHODS: HER-2/neu and ER/PR expression was analyzed by enzyme-linked immunosorbent assay (ELISA) and enzyme immunoassay (EIA), respectively, in 14 human breast cancer cell lines, some of which had been transfected with the HER-2/neu gene. For the clinical study population, HER-2/neu protein levels were assessed by ELISA (cohort A, n = 665), and HER-2/neu gene copy number was determined using fluorescence in situ hybridization (cohort B, n = 894). ER/PR expression was analyzed by EIA (cohort A) or radioligand binding (cohort B). Associations between HER-2/neu and ER/PR expression were analyzed using Spearman's rho correlation and the chi-square test, and absolute levels were compared using the Mann-Whitney U test. All statistical tests were two-sided. RESULTS: HR-positive human breast cancer cell lines transfected with the HER-2/neu gene expressed statistically significantly lower levels of ER and PR than parental lines. In the clinical cohorts, levels of HER-2/neu overexpression and gene amplification were inversely correlated with ER/PR levels (Cohort A [n = 112]: for ER, r = -0.34, P<.001; for PR, r = -0.24, P =.010. Cohort B [n = 188]: for ER, r = -0.39, P<.001; for PR, r = -0.26, P<.001). Among patients with HR-positive tumors, HER-2/neu-positive tumors had statistically significantly lower ER/PR levels than HER-2/neu-negative ones (Cohort A: for ER, median = 25 fmol/mg [interquartile range [IQR] = 13-78] versus median = 38.5 fmol/mg [IQR = 17-99] and P =.031; for PR, median = 35 fmol/mg [IQR = 12-119] versus median = 88.5 fmol/mg [IQR = 22-236] and P<.001. Cohort B: for ER, median = 44 fmol/mg [IQR = 13-156] versus median = 92 fmol/mg [IQR = 35-235] and P<.001; for PR, median = 36 fmol/mg [IQR = 13-108] versus median = 84 fmol/mg [IQR = 24-250] and P<.001). Patients with higher levels of HER-2/neu overexpression or amplification had statistically significantly lower levels of ER/PR than patients with lower levels of HER-2/neu overexpression or amplification. CONCLUSION: Because absolute HR levels are strongly related to response to hormone therapy in primary and advanced breast cancer, reduced ER/PR expression may be one mechanism to explain the relative resistance of HER-2/neu-positive:HR-positive tumors to hormone therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citationStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationTamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Flexible regression models with cubic splines
Durrleman, S., & Simon, R. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080504 · Cited by 2,689
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Self-citationEstrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Pauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., & Slamon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3651 · Cited by 670
Self-citation
Cited by
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Self-citationAssessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Self-citationKonecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Self-citationTriple-negative breast cancer: therapeutic options
Cleator, S., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 882
Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., Lehle, M., Feyereislova, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6847 · Cited by 843
HER2: Biology, Detection, and Clinical Implications
Gutierrez, C., & Schiff, R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0454-rar.1 · Cited by 652
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy
Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., & Bloom, K. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-4-307 · Cited by 610
Emerging use of nanoparticles in diagnosis and treatment of breast cancer
Yezhelyev, M. V., Gao, X., Xing, Y., Al-Hajj, A., Nie, S., & O'Regan, R. M. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70793-8 · Cited by 577
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry
Xing, Y., Chaudry, Q., Shen, C., Kong, K. Y., Zhau, H. E., Chung, L. W., Petros, J. A., O'Regan, R. M., Yezhelyev, M. V., Simons, J. W., et al. (2007) · Nature Protocols · doi:10.1038/nprot.2007.107 · Cited by 528
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
Cui, X., Schiff, R., Arpino, G., Osborne, C. K., & Lee, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.004 · Cited by 514
Pegram, M. D., Konecny, G. E., O'Callaghan, C., Beryt, M., Pietras, R., & Slamon, D. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh131 · Cited by 512
Self-citationSauter, G., Lee, J., Bartlett, J. M. S., Slamon, D. J., & Press, M. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8197 · Cited by 509
Self-citationArpino, G., Weiss, H., Lee, A. V., Schiff, R., De Placido, S., Osborne, C. K., & Elledge, R. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji249 · Cited by 484
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Mohsin, S. K., & Osborne, C. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031212 · Cited by 462
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Dai, X., Xiang, L., Li, T., & Bai, Z. (2016) · Journal of Cancer · doi:10.7150/jca.13141 · Cited by 440
Biologic and therapeutic role of HER2 in cancer
Ménard, S., Pupa, S. M., Campiglio, M., & Tagliabue, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206779 · Cited by 432
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
Linden, H. M., Stekhova, S. A., Link, J. M., Gralow, J. R., Livingston, R. B., Ellis, G. K., Petra, P. H., Peterson, L. M., Schubert, E. K., Dunnwald, L. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3810 · Cited by 394
Filardo, E. J., Graeber, C. T., Quinn, J. A., Resnick, M. B., Giri, D., DeLellis, R. A., Steinhoff, M. M., & Sabo, E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0860 · Cited by 361
Fehm, T., Müller, V., Aktas, B., Janni, W., Schneeweiss, A., Stickeler, E., Lattrich, C., Löhberg, C. R., Solomayer, E., Rack, B., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1163-x · Cited by 353
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Konecny, G. E., Meng, Y. G., Untch, M., Wang, H.-J., Bauerfeind, I., Epstein, M., Stieber, P., Vernes, J.-M., Gutierrez, J., Hong, K., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0951-3 · Cited by 318
Self-citationA new genome‐driven integrated classification of breast cancer and its implications
Dawson, S., Rueda, O. M., Aparicio, S., & Caldas, C. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.19 · Cited by 306
Targeted Therapy in Breast Cancer
Ross, J. S., Fletcher, J. A., Bloom, K. J., Linette, G. P., Stec, J., Symmans, W. F., Pusztai, L., & Hortobagyi, G. N. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400001-mcp200 · Cited by 303
Triple negative breast cancers: Clinical and prognostic implications
Dawson, S. J., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266
Dowsett, M., Cuzick, J., Wale, C., Howell, T., Houghton, J., & Baum, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.4829 · Cited by 260
Arpino, G., Green, S. J., Allred, D. C., Lew, D., Martino, S., Osborne, C. K., & Elledge, R. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0110 · Cited by 255
MEK–ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes
Fujii, S., Tokita, K., Wada, N., Ito, K., Yamauchi, C., Ito, Y., & Ochiai, A. (2011) · Oncogene · doi:10.1038/onc.2011.118 · Cited by 137
Bender, C. M., Gentry, A. L., Brufsky, A. M., Casillo, F. E., Cohen, S. M., Dailey, M. M., Donovan, H. S., Dunbar-Jacob, J., Jankowitz, R. C., Rosenzweig, M. Q., et al. (2014) · Oncology Nursing Forum · doi:10.1188/14.onf.274-285 · Cited by 131
“About 80% of breast cancers express hormone receptors (Konecny et al., 2003).”
Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells
Chang, C. J., Chiu, J. H., Tseng, L. M., Chang, C. H., Chien, T. M., Wu, C. W., & Lui, W. Y. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01676.x · Cited by 80
Metadata
- Authors
- Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., Wang, H.-J., Beryt, M., Seshadri, R., Hepp, H., & Slamon, D. J.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-15
- Volume
- 95
- Issue
- 2
- Pages
- 142-153
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2145257123
- Cited by
- 588
- References
- 42
- FWCI
- 16.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.